Modified Alginates for Anti-Fibrotic Materials and Applications

Exclusively Licensed

Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.

Researchers

Robert Langer / Omid Veiseh / Joshua Doloff / Arturo Vegas / Minglin Ma / Daniel Anderson

Departments: Office of the Institute Professors, Department of Chemical Engineering
Technology Areas: Biomaterials & Bioelectronics: Medical Device Coatings, Tissue Repair / Biotechnology: Tissue Engineering / Chemicals & Materials: Polymers / Therapeutics: Regenerative Medicine
Impact Areas: Healthy Living

  • modified alginates for anti-fibrotic materials and applications
    Italy | Granted | 3,368,085
  • modified alginates for use as anti-fibrotic materials
    United States of America | Granted | 10,709,818
  • modified alginates for anti-fibrotic materials and applications
    United States of America | Granted | 10,729,818
  • modified alginates for anti-fibrotic materials and applications
    Mexico | Granted | 404,406
  • modified alginates for anti-fibrotic materials and applications
    New Zealand | Granted | 742,800
  • modified alginates for anti-fibrotic materials and applications
    India | Granted | 522,851
  • modified alginates for anti-fibrotic materials and applications
    Singapore | Pending
  • modified alginates for anti-fibrotic materials and applications
    South Africa | Granted | 2,018
  • modified alginates for anti-fibrotic materials and applications
    European Patent Convention | Granted | 3,368,085
  • modified alginates for anti-fibrotic materials and applications
    United States of America | Granted | 11,090,413
  • modified alginates for anti-fibrotic materials and applications
    United States of America | Pending
  • modified alginates for anti-fibrotic materials and applications
    Russian Federation | Pending
  • modified alginates for anti-fibrotic materials and applications
    Hong Kong | Granted | 1,260,309
  • modified alginates for anti-fibrotic materials and applications
    United States of America | Granted | 12,097,307
  • modified alginates for anti-fibrotic materials and applications
    Belgium | Granted | 3,368,085
  • modified alginates for anti-fibrotic materials and applications
    Switzerland | Granted | 3,368,085
  • modified alginates for anti-fibrotic materials and applications
    Germany | Granted | 3,368,085
  • modified alginates for anti-fibrotic materials and applications
    Denmark | Granted | 3,368,085
  • modified alginates for anti-fibrotic materials and applications
    Spain | Granted | 3,368,085
  • modified alginates for anti-fibrotic materials and applications
    France | Granted | 3,368,085
  • modified alginates for anti-fibrotic materials and applications
    United Kingdom | Granted | 3,368,085
  • modified alginates for anti-fibrotic materials and applications
    Ireland | Granted | 3,368,085

License this technology

Interested in this technology? Connect with our experienced licensing team to initiate the process.

Sign up for technology updates

Sign up now to receive the latest updates on cutting-edge technologies and innovations.

More Technologies